Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Price, News & Analysis

Rubius Therapeutics logo

About Rubius Therapeutics Stock (NASDAQ:RUBY)

Advanced Chart

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.02
$0.06
52-Week Range
$0.00
$0.38
Volume
755,858 shs
Average Volume
1.15 million shs
Market Capitalization
$5.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Stock News Headlines

How to Get the Exclusive Rubius Fortnite Drop
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Rubius Therapeutics Inc RUBY
RUBY - Rubius Therapeutics, Inc.
North American Morning Briefing: Alphabet, -2-
See More Headlines

RUBY Stock Analysis - Frequently Asked Questions

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.01.

Rubius Therapeutics (RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rubius Therapeutics investors own include Meta Platforms (META), Sorrento Therapeutics (SRNE), Pfizer (PFE), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Tesla (TSLA) and Athenex (ATNX).

Company Calendar

Last Earnings
11/08/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
0.34

Miscellaneous

Free Float
85,687,000
Market Cap
$5.16 million
Optionable
Not Optionable
Beta
2.59
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:RUBY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners